Jonathan Kaufman MD

Contact Information:

Phone: 404-778-1900

Email: jlkaufm@emory.edu

View Emory directory entry

School/Division:

Assoc Professor

SOM: HMO: Hematology

School Of Medicine

Other Affiliations:

No affiliations have been saved.

External Links (e.g. Departmental web site, iTunes lectures, etc.):

No external links have been saved.

Degrees Held:

No degrees have been saved.

Research Interests:

No research interests have been saved.

Biography/Description of Research:

No biography information has been saved.

Works 1-10 of 16

  1. 1
  2. 2

Article

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

by Meletios A. Dimopoulos; Jesus San-Miguel; Andrew Belch; Darrell White; Lotfi Benboubker; Gordon Cook; Merav Leiba; James Morton; P. Joy Ho; Kihyun Kim; Naoki Takezako; Philippe Moreau; Jonathan Kaufman; Heather J. Sutherland; Marc Lalancette; Hila Magen; Shinsuke Iida; Jin Seok Kim; H. Miles Prince; Tara Cochrane; Albert Oriol; Nizar J. Bahlis; Ajai Chari; Lisa O'Rourke; Kaida Wu; Jordan M. Schecter; Tineke Casneuf; Christopher Chiu; David Soong; A. Kate Sasser; Nushmia Z. Khokhar; Herve Avet-Loiseau; Saad Z. Usmani

2018

Article

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

by Shaji K. Kumar; Jesus G. Berdeja; Ruben Niesvizky; Sagar Lonial; Jacob P. Laubach; Mehdi Hamadani; A. Keith Stewart; Parameswaran Hari; Vivek Roy; Robert Vescio; Jonathan Kaufman; Deborah Berg; Eileen Liao; S. Vincent Rajkumar; Paul G. Richardson

2019

Article

Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab

by Luis Fayad; Fritz Offner; Mitchell R. Smith; Gregor Verhoef; Peter Johnson; Jonathan Kaufman; Ama Rohatiner; Anjali Advani; James Foran; Georg Hess; Bertrand Coiffier; Myron Czuczman; Eva Giné; Simon Durrant; Michelle Kneissl; Kenneth T. Luu; Steven Y. Hua; Joseph Boni; Erik Vandendries; Nam H. Dang

2013

Article

A Phase 1 and 2 Study of Filanesib Alone and in Combination With Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma

by Jatin J. Shah; Jonathan Kaufman; Jeffrey A. Zonder; Adam D. Cohen; William I. Bensinger; Brandi Hilder; Selena Rush; Duncan Walker; Brian Tunquist; Kevin Litwiler; Mieke Ptaszynski; Robert Z. Orlowski; Sagar Lonial

2017

Article

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

by Taro Hitosugi; Sumin Kang; Matthew G. Vander Heiden; Tae-Wook Chung; Shannon Elf; Katherine Lythgoe; Shaozhong Dong; Sagar Lonial; Xu Wang; Georgia Chen; Jianxin Xie; Ting-Lei Gu; Roberto D. Polakiewicz; Johannes L. Roesel; Titus J. Boggon; Fadlo Khuri; D. Gary Gilliland; Lewis C. Cantley; Jonathan Kaufman; Jing Chen

2009

Article

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

by Roberto Mina; Nisha S. Joseph; Francesca Gay; Efstathios Kastritis; Maria Teresa Petrucci; Jonathan Kaufman; Vittorio Montefusco; Maria Gavriatopoulou; Francesca Patriarca; Paola Omede; Lawrence Boise; Maria Roussou; Nicola Giuliani; Stefania Oliva; Massimo Offidani; Angelo Belotti; David Jaye; Lorenzo De Paoli; Evangelos Terpos; Sagar Lonial; Mario Boccadoro; Ajay Nooka; Meletios A. Dimopoulos

2020